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Abstract 
Tolcapone, a brain penetrant selective inhibitor of catechol-O-methyltransferase (COMT) 
devoid of psychostimulant properties, improves cognition and cortical information processing in 
rested volunteers, depending on the genotype of the functional Val158Met polymorphism of COMT. 
The impact of this common genetic variant on behavioral and neurophysiological markers of 
increased sleep need after sleep loss is controversial. Here we investigated the potential usefulness 
of tolcapone to mitigate consequences of sleep deprivation on lapses of sustained attention, and 
tested the hypothesis that dopamine signaling in the prefrontal cortex (PFC) causally contributes to 
neurobehavioral and neurophysiological markers of sleep homeostasis in humans. We first 
quantified in 73 young male volunteers the impact of COMT genotype on the evolution of 
attentional lapses during 40 hours of extended wakefulness. Subsequently, we tested in an 
independent group of 30 young men whether selective inhibition of COMT activity with tolcapone 
counteracts attentional and neurophysiological markers of elevated sleep need in a genotype-
dependent manner. Neither COMT genotype nor tolcapone affected brain electrical activity in 
wakefulness and sleep. By contrast, COMT genotype and tolcapone modulated the sleep-loss 
induced impairment of vigilant attention. More specifically, Val/Met heterozygotes produced twice 
as many lapses after a night without sleep than Met/Met homozygotes. Unexpectedly, tolcapone 
further deteriorated the sleep loss-induced performance deficits when compared to placebo, 
particularly in Val/Met and Met/Met genotypes. The findings suggest that PFC dopaminergic tone 
regulates sustained attention after sleep loss according to an inverse U-shape relationship, 
independently of neurophysiological markers of elevated sleep need.  
 
  
 3 
Introduction 
Elevated sleepiness and impaired vigilance due to medical disorders, shift work or jetlag are 
highly prevalent in society. Despite the risk of adverse effects, abuse and dependence, modafinil and 
psychostimulant medications are frequently used to treat pathological sleepiness in patients 
suffering from narcolepsy, attention-deficit-hyperactivity disorder, circadian sleep-wake rhythm 
disorders, or behaviorally-induced insufficient sleep (Farah, 2015). Furthermore, pronounced inter-
individual variation exists in the response to psychostimulants in sleep-disordered or sleep-deprived 
individuals. It was previously proposed that functional variation in the catechol-O-methyltransferase 
(COMT) gene may contribute to these differences (Bodenmann et al, 2009; Holst et al, 2016), yet 
evidence for a causal genotype-phenotype association is currently lacking. 
Prefrontal cortex (PFC) dopaminergic neurotransmission contributes to a wide range of 
cognitive and neuropsychiatric phenotypes (Goldman-Rakic et al, 2000; Tunbridge et al, 2006), and 
the COMT gene encodes the main enzyme degrading catecholamines in the PFC (Matsumoto et al, 
2003). A common valine-to-methionine substitution at codon 158 of COMT protein (Val158Met 
single nucleotide polymorphism [SNP]; SNP-Id: rs4680) drastically reduces enzymatic activity (Chen 
et al, 2004), leading to elevated PFC dopaminergic tone in Met/Met homozygotes when compared 
to Val/Val homozygotes (Tunbridge et al, 2006). While COMT genotype modulates PFC functioning 
(Egan et al, 2001; Tunbridge et al, 2006), some effects of this polymorphism may only become 
prominent when the dopamine system is challenged, such as with behavioral or pharmacological 
interventions including sleep deprivation (Bodenmann et al, 2009; Satterfield et al, 2017) and 
administration of the brain penetrant COMT inhibitor tolcapone (Barkus et al, 2016; Farrell et al, 
2012; Giakoumaki et al, 2008). Tolcapone is a non-stimulant drug thought to lead to relatively 
specific increases in PFC dopamine (Apud et al, 2007; Farrell et al, 2012; Giakoumaki et al, 2008). 
Because it hardly affects striatal dopaminergic transmission, tolcapone may mitigate 
subjective and behavioral consequences of sleep deprivation without unwanted psychostimulant 
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adverse effects. In addition, it offers the unique opportunity to dissect distinct roles of dopaminergic 
circuities in sleep-wake regulation. The impact of mesocortical dopaminergic neurotransmission for 
sleep-wake phenotypes in humans is controversial (Dauvilliers et al, 2015). More specifically, by 
studying dopaminergic mechanisms of sustained attention after sleep deprivation, the wake 
promoting agent modafinil was virtually ineffective in Met/Met homozygotes of COMT (Bodenmann 
et al, 2009). By contrast, in homozygous Val/Val allele carriers, modafinil maintained optimal 
performance on the psychomotor vigilance test (PVT) throughout 40 hours of prolonged 
wakefulness (Bodenmann et al, 2009). These results were compatible with a hypothesized inverse 
U-shape relationship in the response of the PFC to elevated dopaminergic neurotransmission 
(Mattay et al, 2003). Intriguingly, neither COMT genotype nor modafinil altered the waking-induced 
rebound in electroencephalographic (EEG) slow-wave activity (SWA, spectral power within the 0.75-
4.5 Hz range) in non-rapid-eye-movement (NREM) sleep (Bodenmann et al, 2009; Bodenmann and 
Landolt, 2010). In contrast to this observation, another study suggested that the Val158Met 
polymorphism of COMT could serve as a genetic biomarker for predicting individual differences in 
sleep physiology (Goel et al, 2011). Reconciling this discrepancy is important because EEG SWA is the 
best established neurophysiologic biomarker of the homeostatic facet of sleep-wake regulation 
(Borbély, 1982). 
Here we aimed at clarifying the role of COMT in sleep-wake regulation and at testing the 
causality of the suggested genotype-phenotype associations. We first investigated the impact of 
COMT genotype on sustained attention after one night without sleep in 73 male volunteers. 
Subsequently, we examined the interaction of COMT genotype, tolcapone and sleep deprivation on 
PVT performance and neurophysiological markers of sleep-wake regulation in 30 young men. Given 
their baseline differences in COMT enzymatic activity, we hypothesized that sleep loss would 
differently impair sustained attention in Val/Val, Val/Met and Met/Met allele carriers, and that 
Val/Val homozygotes would benefit from tolcapone because it counteracts the overactive COMT and 
associated deficit in PFC dopaminergic tone. Our results show that tolcapone had no beneficial 
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effect in any genotype, but further deteriorated attentional lapses after sleep deprivation in Val/Met 
and Met/Met allele carriers without affecting EEG markers of sleep homeostasis. The data are 
consistent with an inverted U-shape relationship between mesocortical dopaminergic signaling and 
sustained attention after sleep loss. 
 
Materials and Methods 
Sleep deprivation (SD) study 
Participants and genotyping 
The analysis of sustained vigilant attention during extended wakefulness relied on the data 
of 52 male participants of three previously reported sleep deprivation studies (Hefti et al, 2013; 
Holst et al, 2014), as well as 21 additional male volunteers completing an analogous protocol. 
Female subjects were excluded because COMT gene expression is modulated by estrogen-regulating 
sequences (Xie et al, 1999) and interactions between sex and genotype were previously reported in 
humans and mice (Dauvilliers et al, 2002; Gogos et al, 1998). No study participant worked shifts or at 
night, travelled more than two time zones in the last three months, nor suffered from any known 
disorder of the nervous system or an acute medical condition. Participants were free of medication 
and recreational drug use and consumption of excessive amounts of alcohol (< five “drinks” per 
week) or caffeine (< three cups of coffee or equivalent per day). They were enrolled into the studies 
when a pre-study screening night in the laboratory confirmed the absence of any sleep disorder, and 
sleep efficiency defined as the percentage of polysomnographically recorded total sleep time per 
time in bed (i.e., elapsed time between ‘lights-off’ and ‘lights-on’) in the screening night equaled 
> 80 %. According to the principles in the Declaration of Helsinki, all study protocols were approved 
by the ethics committee of the Canton of Zürich for human research. Written informed consent was 
obtained from all volunteers, who received a financial compensation for their participation. 
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In the 52 participants of the previous studies, genomic DNA was extracted from 3 ml fresh 
EDTA-blood (Wizard® Genomic DNA Purification Kit, Promega, Madison, WI). The Val158Met 
polymorphism of COMT was determined using Taqman® SNP Genotyping Assays (Life Technologies 
Europe B.V.). Allelic discrimination analysis was performed with SDS v2.2.2 software (Applied 
Biosystems, Foster City, CA, USA). In 30 participants, DNA was isolated from 200 μl blood using 
NucleoSpin® Blood (Macherey Nagel GmbH Co. KG). In the 21 additional participants, genomic DNA 
was extracted from 2 ml saliva samples using Oragene® DNA kit (DNA Genotek Inc., Ottawa, 
Canada). The Val158Met genotypes of COMT were determined by PCR followed by sequencing. 
Primers used for amplification on MJ Research PTC-225 thermal cyclers (MJ Research/Bio-Rad, Reno, 
USA) were 5'-GAT CCA AGT TCC CCT CTC TC-3' and 5'-GGT GGT CCA CAA GTG TGG T-3'. The amplified 
DNA sequences were then sequenced using the Sanger chain-termination method. A Sephadex G-50 
purification step was applied according to the manufacturer’s instructions. The capillary gel 
electrophoresis and laser detection of the purified DNA products (351 bp) was performed with an 
ABI PRISM 3100 or ABI PRISM 3730 Genetic Analyser (Life Technologies, Zug, Switzerland). The DNA 
reads from the sequencer were analyzed using the Sequencing Analysis 5.2 and SeqScape version 2.5 
(both Life Technologies, Zug CH) softwares. All genotypes were replicated at least once for 
independent confirmation. 
The demographic characteristics of the participants in the ‘SD study’ are summarized in 
Table 1. The Val/Val, Val/Met and Met/Met genotype groups did not differ with respect to age, BMI, 
habitual alcohol and caffeine consumption, chronotype, subjective daytime sleepiness and anxiety. 
 
Study protocol 
After 8-hour adaptation and baseline nights (00:00-8:00), subjects were kept awake for 40 
hours, and given a 10-hour sleep opportunity for recovery. During prolonged wakefulness, subjects 
were constantly supervised and completed questionnaires, cognitive and neurobehavioral tasks, and 
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waking EEG recordings at regular time intervals. All participants abstained from caffeine during two 
weeks prior to the start of the experiments, and from alcohol and daytime naps during at least three 
days before the studies. They were required to spend 8 hours in bed (00:00-8:00) on the three nights 
before each study block. Compliance with these instructions was verified by actigraphy and sleep-
wake diaries, as well as determination of saliva caffeine and breath alcohol levels upon arrival in the 
laboratory for sleep recordings. All studies were completed in the sleep lab of the Institute of 
Pharmacology and Toxicology at the University of Zürich. 
 
Psychomotor vigilance test (PVT) 
A computerized version of the Psychomotor Vigilance Test (PVT) (e-Prime software, 
Psychology Software Tools Inc., Pittsburgh, PA, USA) was used to assess sustained vigilant attention 
(Basner and Dinges, 2011). Each test consisted of 100 trials (lasting approximately 10 min), in which 
a numeric count-up timer appeared at random intervals on the computer screen. Participants had to 
press the “space” key as soon as possible upon detection of the stimulus. They completed a training 
session before the first adaptation night. Lapses of attention (reaction times [RT] > 500 ms), ‘errors 
of commission’ (RT < 100 ms) and ‘correct’ responses (100 ms < RT < 500 ms) were considered. 
Speed, defined as the reciprocal values of RT, was calculated for correct responses only. Outliers 
were defined as values below and above 2 standard deviations of the mean, and incomplete 
sessions (< 100 trials) were excluded from analysis. To assess ‘time on task’ (TOT) dependent 
behavior, the task was subdivided into 5 equal quintiles, each containing 20 trials. 
 
Sleep deprivation and tolcapone (SD&T) study 
Participants and genotyping 
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To test causality in the observed COMT genotype-phenotype association, 30 participants 
were enrolled for a separate study (‘SD&T study’; see supplementary Fig. S1). The study protocol 
was approved by the ethics committee of the Canton of Zürich for human research, as well as the 
Swiss Agency for Therapeutic Products. Written informed consent was obtained from all participants 
who received financial compensation for their participation. The Phase I Clinical Trial was registered 
on www.clinicaltrials.gov (identifier: NCT02080715). Data collection was completed between August 
2013 and April 2014. 
The DNA for genotyping was isolated from 200 μl blood using NucleoSpin® Blood (Macherey 
Nagel GmbH Co. KG). The Val158Met polymorphism of COMT was determined as described above. 
The Val/Val, Val/Met and Met/Met genotype groups did not differ with respect to age, BMI, 
habitual alcohol and caffeine consumption, chronotype, subjective daytime sleepiness and sleep 
quality, as well as neuropsychiatric personality traits (Table 2). 
 
Study protocol 
Study protocol and testing of performance on the PVT during prolonged waking were the 
same as described above. In addition, mood, tiredness and sleepiness were quantified at 3-hour 
intervals with the following validated questionnaires: Profile of Mood States (POMS; fatigue, vigor, 
irritability, depression) (McNair et al, 1992); Visual Analogue Scales (VAS; mood, energy, motivation 
and excitation); Tiredness Symptom Scale (TSS) (Schulz et al, 1991) and Karolinska Sleepiness Scale 
(KSS) (Åkerstedt and Gillberg, 1990). A morning questionnaire was administered shortly after each 
night to rate subjective sleep quality, including number of awakenings, total duration of time spent 
awake, subjective sleep latency, sleep intensity and mood upon awakening. 
 
Waking EEG recordings 
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In each study block, participants also completed at 3-hour intervals 14 wake EEG recordings, 
the first initiated 15 min after ‘lights on’ after the baseline nights. Recordings consisted of a 3-min 
period with eyes closed and a 5-min period with eyes open, while sitting immobile and fixating a dot 
on the wall. Subjects were alerted through the intercom whenever signs of drowsiness were 
detected (e.g., reduced EEG alpha activity or rolling eyes). Continuous EEG, bipolar electrooculogram 
(EOG), electromyogram (EMG), and electrocardiogram (ECG) were recorded with Rembrandt® 
Datalab (Version 8; Embla Systems, Broomfield, CO, USA) and the polygraphic amplifier Artisan® 
(Micromed, Mogliano Veneto, Italy). Analog signals were conditioned by a high-pass filter (EEG: -3 
dB at 0.15 Hz; EMG: 10 Hz; ECG: 1 Hz) and an antialiasing low-pass filter (-3 dB at 67.2 Hz), digitized 
and stored with a resolution of 256 Hz (sampling frequency of 256 Hz). Ten bipolar EEG derivations 
along the right and left anteroposterior axes were recorded. The data of the C3A2 derivation are 
reported here; artifacts were visually identified. Power spectra (Fast Fourier Transform, Hanning 
window) of artifact-free, 50%-overlapping 2-s epochs were computed with MATLAB® (The 
MathWorks Inc., Natick, MA, USA), resulting in a 0.5 Hz frequency resolution. Frequency bins 
between 1 and 20 Hz were analyzed. To compare the waking EEG between baseline and after sleep 
deprivation, mean values recorded at 8:00, 11:00, 14:00 and 17:00 on the second day of prolonged 
wakefulness were expressed as a percentage of the respective mean values of the baseline day. 
 
Polysomnographic recordings 
Continuous recording of EEG, EOG, EMG, and ECG was performed during all nights. Standard 
sleep stages (Rechtschaffen and Kales, 1968) were visually scored in 20-s epochs (C3A2 derivation) 
with Rembrandt® Analysis Manager (Version 8; Embla Systems, Broomfield, CO, USA). Movement- 
and arousal-related artifacts were visually identified and eliminated. EEG spectra (FFT routine, 
Hanning window, 50% overlapping 4-s epochs, 0.25 Hz resolution) were calculated with MATLAB®, 
averaged over 5 consecutive 4-s epochs, and matched with the sleep scores. To compute all-night 
 10 
power spectra in NREM sleep (stages 2, 3 and 4) and REM sleep, all artifact-free 20-s values were 
averaged. NREM/REM sleep cycles were defined according to Feinberg and Floyd (1979). Data 
analyses were restricted to the first 8 hours of the recovery nights. Relative EEG power values in the 
recovery nights were normalized to the average all-night EEG power of the two baseline nights. 
 
Tolcapone 
Tolcapone is an orally active, reversible, competitive inhibitor of COMT. Following oral 
administration, the compound crosses the blood brain barrier and has a specific effect on PFC 
dopamine neurotransmission (Napolitano et al, 1995; Rojo et al, 2001). Two doses of 100 mg 
tolcapone, in the form of capsules, were administered to all subjects after 11 (at 7:00 pm) and 23 
hours (at 7:00 am) of prolonged wakefulness according to a randomized, double-blind, placebo-
controlled, crossover design. In vitro work suggests that at a dose of 100 mg, tolcapone induces 
maximum inhibition (72 %) of COMT enzymatic activity after approximately 1-1.5 hours, while 
activity returns to baseline levels after roughly 13 hours (Dingemanse et al, 1995). These pharmaco-
dynamic properties of tolcapone permitted us to address the question whether COMT inhibition 
during prolonged wakefulness affects the sleep EEG independently of an acute pharmacological 
effect. Capsules and random allocation sequence were produced by the ‘Kantonsapotheke Zürich’ by 
homogenizing commercial Tasmar® Tolcaponum 100 mg tablets (distribution: MEDA Pharma GmbH, 
Wangen-Brüttisellen, Switzerland) with mannitol (Siegfried Ltd., Zofingen, Switzerland); placebo 
capsules of identical appearance contained only mannitol. Verum and placebo were administered 
one week apart to two randomization groups, containing 5 individuals of each COMT genotypes and 
differing by the sequence of drug administration. 
Due to the potential hepatotoxicity of tolcapone, liver functions were assessed before and 
after the experiment. They were required to lay within normal range for study participation (alanine 
transaminase: < 82 U/l; aspartate transaminase: < 76 U/l). 
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Statistical analyses 
Performance on the PVT was assessed with SAS 9.2 software (SAS Institute, Cary, North 
Carolina) similarly to previous studies (Holst et al, 2017). Linear mixed models for repeated 
measures with the random effect ‘subject’, the between-subjects factor ‘genotype’ (Val/Val, 
Val/Met, Met/Met), and the within-subjects factors ‘day’ (baseline, sleep deprivation), ‘time’ (14 
sessions), ‘time on task’ (quintiles 1-5), ‘treatment’ (placebo, tolcapone), ‘condition’ (baseline night, 
placebo recovery night, tolcapone recovery night), and ‘NREM sleep episode’ (1-4) were conducted 
as specified in text and Figure legends. If not stated otherwise, estimated means and standard errors 
of corresponding mixed models are illustrated. Numbers of lapses were defined as percentage 
within each quintile (‘lapse frequency’) and absolute EEG power densities were log-transformed 
before statistical analyses, to approximate a normal distribution. Effect sizes (partial eta squared: 
ηP2) were calculated from corresponding ANOVA F-values and degrees of freedom. Effect sizes of 
0.01, 0.059 and 0.138 are considered small, moderate and large (Cohen, 2013; Richardson, 2011). 
Significance level was set at α < 0.05. Bonferroni-corrected post-hoc tests to correct for multiple 
comparisons are reported where appropriate. 
 
Results 
COMT genotype contributes to individual differences in attentional lapses after sleep deprivation 
Prolonged wakefulness and time on task increased the number of lapses on the PVT, 
reflecting well-established homeostatic and circadian influences (‘time’: F5,3720 = 12.00, p < 0.0001, 
ηP2 = 0.016; ‘day’: F1,3720 = 500.9 p < 0.0001, ηP2 = 0.119; ‘time on task’: F4,3720 = 22.0, p < 0.0001, ηP2 
= 0.023) (Fig. 1A). Moreover, COMT genotype modulated the impairment in PVT performance over 
time (‘genotype’ x ‘time’ interaction: F10,3720 = 2.47, p < 0.006, ηP2 = 0.007). To better illustrate this 
main finding of the ‘SD study’, Fig. 1B depicts mean lapse frequency on the days before and after 
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sleep deprivation. While all genotypes performed equally well without virtually any lapses in 
baseline, they clearly differed on the second day (‘genotype’ x ‘day’ interaction: F2,3720 = 19.16, p < 
0.0001, ηP2 = 0.010). Specifically, Val/Met heterozygotes produced almost the double number of 
lapses (11.8 ± 1.0, n = 35) on the day after sleep loss when compared to Met/Met homozygotes (6.2 
± 1.3, n = 21) (Fig. 1B). A similar yet less striking modulation by COMT genotype was observed in the 
placebo condition in the 30 independent participants of the ‘SD&T study’ (‘genotype’ x ‘day’ 
interaction: F2,1524 = 6.0, p < 0.003, ηP2 = 0.008) (see Fig. 3B). 
 
COMT genotype and COMT inhibition have no impact on neurophysiological and behavioral markers 
of elevated sleep pressure 
To tackle the question whether the build-up of homeostatically regulated sleep pressure is 
modulated by COMT genotype and selective pharmacological inhibition of COMT enzymatic activity, 
detailed quantitative analyses of the EEG in wakefulness and sleep were performed. On the baseline 
day, absolute spectral power between 1 and 20 Hz averaged over all waking EEG recordings from 
8:00 to 17:00 was similar in all genotypes (‘genotype’: F2,25 < 3.8, pall > 0.06). Sleep deprivation 
increased EEG activity in all bins below 9 Hz and above 11.5 Hz (‘condition’: F1,72 > 3.89, pall < 0.05, 
ηP2 = 0.051). Fig. 2a illustrates the evolution of delta-theta activity (1-9 Hz band) across prolonged 
wakefulness in Val/Val, Val/Met and Met/Met genotypes of COMT. In all genotypes, the evolution of 
EEG activity reflected similar homeostatic and circadian influences (‘time’: F13,261 = 20.3, p < 0.0001, 
ηP2 = 0.502; ‘genotype’: F2,26 = 2.49, p > 0.1), which was indistinguishable between tolcapone and 
placebo (treatment’: F1,71 = 0.18, p > 0.6; ‘genotype’ x ‘treatment’ interaction: F2,71 = 0.69, p > 0.5). 
Compared to the baseline night, sleep deprivation increased EEG SWA, slow wave sleep, 
total sleep time and sleep efficiency in the recovery night irrespectively of COMT genotype and 
tolcapone treatment (Fig. 2B and supplementary Table S1). Absolute SWA values, the dissipation of 
SWA across consecutive NREM sleep episodes in baseline and recovery nights, as well as the relative 
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increase in SWA after sleep deprivation were similar among genotypes and treatment conditions. 
More specifically, 3-way mixed-model ANOVA with the factors ‘genotype’, ‘condition’ and ‘NREM 
sleep episode’ yielded significant main effects and interaction of ‘condition’ (F2,295 = 84.3, p < 0.0001, 
ηP2 = 0.363) and ‘episode’ (F3,293 = 488.7, p < 0.0001, ηP2 = 0.833; ‘condition’ x ‘episode’ interaction: F 
6,293 = 11.8, p < 0.0001, ηP2 = 0.195), yet no effects involving ‘genotype’. Furthermore, no significant 
main effects of ‘genotype’ or ‘treatment’, or interactions with the factor ‘condition’ were observed in 
visually scored sleep variables and subjective ratings of sleep quality (supplementary Table S1). 
Sleep deprivation also increased sleepiness, fatigue, tiredness and irritability, and reduced 
response speed on the PVT, vigor, energy, motivation, and mood. These typical effects of prolonged 
wakefulness were not modulated by COMT genotype nor tolcapone treatment (supplementary Fig. 
S2). 
 
Tolcapone enhances attentional lapses after sleep deprivation depending on COMT genotype 
Although they were devoid of effects on neurophysiological and state markers of elevated 
sleepiness after sleep loss, both COMT genotype and tolcapone affected attentional lapses after 
sleep deprivation. Prolonged wakefulness and time-on-task enhanced lapsing also in the ‘SD&T 
study’ (‘time’: F5,2937 = 12.7, p < 0.0001, ηP2 = 0.021; ‘day’: F1,2937 = 768.0, p < 0.0001, ηP2 = 0.207; 
‘time on task’: F4,2937 = 11.1, p < 0.0001, ηP2 = 0.015). Unexpectedly, however, rather than improving 
performance, tolcapone further increased lapse frequency on the day following sleep loss when 
compared to placebo (20.3 ± 1.4 vs. 15.8 ± 1.4; ‘treatment’: F1,2937 = 27.8, p < 0.0001, ηP2 = 0.009; 
‘treatment’ x ‘day’ interaction: F1,2937 = 7.1, p = 0.009, ηP2 = 0.002; Fig. 3A). When analyzing the data 
on a finer time scale, a significant ‘genotype’ x ‘treatment’ x ‘time’ interaction was observed (F10,2937 
= 3.2, p < 0.0005, ηP2 = 0.011). More specifically, intake of tolcapone at 7 am after the night without 
sleep significantly deteriorated performance in Val/Met and Met/Met genotypes when compared to 
placebo (p < 0.05; Fig. 3B). The difference between the treatment conditions was insignificant in the 
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Val/Val genotype. By contrast, in Val/Met heterozygotes, performance between tolcapone and 
placebo still differed at 5 pm, 10 hours after the second tolcapone ingestion. 
 
Discussion 
Because tolcapone appears to be free of major psychostimulant properties and abuse 
potential (Apud et al, 2007), the pharmacodynamic profile of this COMT inhibitor may be beneficial 
to improve vigilance in sleepy patients and healthy individuals undergoing sleep deprivation. Indeed, 
previous research consistently concluded that this compound may improve distinct aspects of 
cognitive functions in Parkinson’s patients (Gasparini et al, 1997), healthy volunteers (Apud et al, 
2007; Farrell et al, 2012; Giakoumaki et al, 2008), as well as rats and mice (Barkus et al, 2016; 
Risbrough et al, 2014; Tomlinson et al, 2015). While we expected that especially individuals with 
high COMT activity (Val/Val genotype) may benefit from pharmacological COMT inhibition, we found 
that tolcapone does not improve sustained attention after prolonged wakefulness in any COMT 
genotype. On the contrary, it increased attentional lapses in Val/Met and Met/Met allele carriers. 
Sustaining focused attention while performing a 10-min PVT is a challenging task, especially 
when sleep deprived. Increased lapsing compared to the rested state has been assumed to reflect 
transient cognitive disruptions referred to as “wake-state instability” (Lim and Dinges, 2008). The 
precise neural bases of how acute total sleep loss impairs sustained attention are currently unknown 
(Ma et al, 2015). Nevertheless, a core brain network comprising dorsomedial, mid- and ventrolateral 
prefrontal cortex, anterior insula, parietal areas, as well as subcortical structures including cerebellar 
vermis, thalamus, basal ganglia, and midbrain subserves vigilant attention (Langner and Eickhoff, 
2013). The midbrain is the origin of three major dopaminergic pathways (Haber, 2014). The 
nigrostriatal pathway projects from the substantia nigra to the striatum (caudate/putamen) and 
plays an important role in motor control. The mesolimbic pathway is associated with the reward 
circuit. This pathway originates in the ventral tegmental area (VTA), connects to several structures of 
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the limbic system, and is important for memory, reward and motivation behaviors. Similarly, the 
mesocortical pathway also originates in VTA, but projects to the frontal cortex and surrounding 
structures. Given that dopaminergic neurotransmission in the mesocortical pathway is primarily 
controlled by COMT (Käenmäki et al, 2010; Sesack, 2014), the present genetic and pharmacogenetic 
data suggest that the mesocortical dopaminergic system importantly contributes to the regulation of 
lapses in sustained attention after sleep deprivation. Nevertheless, it needs to be kept in mind that 
vigilant attention during sleep deprivation is regulated by several neurotransmitters, and yet 
unknown factors and their interactions could influence the current findings. For example, previous 
reports have shown that benefits of the cholinesterase inhibitor, donepezil, were most pronounced 
in study participants whose vigilance clearly declined in the placebo condition when sleep deprived, 
whereas those participants who maintained vigilance when receiving placebo worsened under 
donezepil (Chuah and Chee, 2008; Chuah et al, 2009). Apart from increasing cholinergic 
neurotransmission, donepezil secondarily also influences dopaminergic and noradrenergic signaling. 
In addition, the interpretation of the results should consider that the COMT enzyme, which is 
present in the brain and the periphery, not only metabolizes dopamine but also various other 
compounds including the dopamine derivatives norepinephrine and epinephrine. 
 
 
Sleep deprivation and tolcapone modulate attentional lapses according to an inverse U-shaped 
relationship 
It is well established that genetic variation of COMT modulates body and brain functions 
according to U-shape relationships (e.g., Mattay et al, 2003; Apud et al, 2007; Giakoumaki et al, 
2008; Sesack, 2014). Corroborating the view that dopaminergic agonists can correct behavioral 
consequences of suboptimal PFC dopaminergic signaling, metamphetamine and tolcapone reliably 
improved different aspects of memory, executive functioning, and risk taking in non-sleep-deprived 
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Val/Val allele carriers, but were ineffective or even impaired performance in Met/Met individuals 
(Apud et al, 2007; Farrell et al, 2012; Giakoumaki et al, 2008; Mattay et al, 2003). The present study 
demonstrates that beyond and above COMT genotpye, a pre-existing sleep debt strongly impacts on 
the effects of a pharmacological increase of dopaminergic neurotransmission on brain functions. 
This conclusion is consistent with a previous study, showing that a low dose of modafinil maintained 
optimal sustained attention, executive functioning and subjective well-being for as long as two days 
and one night of prolonged wakefulness in Val/Val homozygotes, yet was ineffective in matched 
Met/Met allele carriers (Bodenmann et al, 2009). The current work extends these findings and 
suggests that similar to other PFC dependent processes such as working memory and risky decision 
making (Farrell et al, 2012; Goldman-Rakic et al, 2000; Tunbridge et al, 2006), there is an inverted U-
shape relationship between dopamine activity in PFC and attentional lapses, and this relationship is 
modulated by sleep loss. 
As schematically illustrated in Fig. 4, the data suggest that lapse frequency on a 10-min PVT 
is optimal in well-rested study participants and indistinguishable among Val/Val, Val/Met and 
Met/Met genotypes of COMT (also see Bodenmann et al, 2009; Goel et al, 2011). Wakefulness 
increases dopamine concentrations in periphery and central nervous system, including nucleus 
accumbens and medial PFC, in rats (Andersen et al, 2005; Léna et al, 2005), as well as human plasma 
(McMorris et al, 2006). Thus, sleep deprivation can be assumed to increase PFC dopamine to super-
optimal levels. Due to the genotype-dependent differences in COMT enzymatic activity and 
associated differences in baseline dopaminergic neurotransmission, the relative increase in 
dopaminergic tone after prolonged waking may be most pronounced in Val/Val, intermediate in 
Val/Met, and weakest in Met/Met genotype, leading to the observed differences in PVT lapses after 
sleep loss. Instead of mitigating the consequences of sleep loss, tolcapone treatment induced even 
more pronounced impairment. Future studies are warranted to probe the dose-effect relationships 
of the interaction between total and partial sleep deprivation and tolcapone, to test whether there 
is an additive interaction of sleep loss and inhibition of COMT. This work will have considerable 
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translational relevance because COMT inhibitors are used as adjunctive treatment in Parkinson’s 
disease and have been considered for patients and people with impaired vigilance due to insufficient 
sleep.  
 
Tolcapone and sleep-wake regulation 
While it is well established that serotonin, histamine and norepinephrine importantly 
contribute to sleep-wake regulation (for recent review, see Holst et al, 2016), the exact roles of 
dopamine in regulating sleep remain incompletely understood. Recent studies in flies, mice and 
humans accumulated convergent evidence that mesolimbic dopaminergic pathways importantly 
contribute to the maintenance of wakefulness, the homeostatic regulation of sleep, arousal, as well 
as sleep-wake dependent behaviors (Andretic et al, 2008; Eban-Rothschild et al, 2016; Holst et al, 
2014, 2017; Oishi et al, 2017; Ueno et al, 2012; Valomon et al, 2014; Volkow et al, 2012; Wisor et al, 
2001). By contrast, the available studies on the impact of the mesocortical pathway and COMT 
activity on sleep-wake regulation are inconclusive. For example, research in large samples of 
individuals studied under field conditions with questionnaires, actigraphy and waking EEG revealed 
no consistent influence on daytime sleepiness and physiological markers of circadian and 
homeostatic sleep-wake regulation (Dauvilliers et al, 2001; Jawinski et al, 2016; Valomon et al, 
2014). Nevertheless, a laboratory study employing a chronic partial sleep restriction protocol 
suggested that Met/Met homozygotes of the Val158Met polymorphism of COMT exhibit a steeper 
decline in EEG slow-wave energy during sleep than Val/Met and Val/Val allele carriers (Goel et al, 
2011). This observation was interpreted to reflect a differential homeostatic response to sleep loss 
among different COMT genotypes. However, another well-controlled study found no differences 
between Val/Val and Met/Met homozygotes in established sleep and EEG markers of sleep 
homeostasis in baseline and after acute total sleep deprivation (Bodenmann et al, 2009; Bodenmann 
and Landolt, 2010). The current investigation confirmed that functional genetic variation and 
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selective pharmacological inhibition of COMT enzymatic activity do not affect established waking 
and sleep EEG markers of sleep homeostasis when challenged by acute total sleep deprivation. The 
data, thus, indicate that the mesocortical dopaminergic system has no major role in regulating sleep 
homeostasis. Supporting this conclusion, the monoaminergic wake-promoting agent, modafinil, and 
the irreversible monoamine oxidase inhibitor, phenelzine, do not alter the dynamics of EEG SWA in 
NREM sleep (Bodenmann and Landolt, 2010; Holst et al, 2014; Landolt et al, 2001). The dissociation 
between sleep-wake dependent changes in neurobehavioral performance, subjective sleepiness and 
neurophysiologic markers of sleep pressure has been highlighted in various previous publications 
(e.g., Leproult et al, 2003; Galliaud et al, 2008; Lim and Dinges, 2008; Holst et al, 2017), suggesting 
that these markers of elevated sleep drive are regulated by different underlying mechanisms. 
 
Main conclusions 
In summary, the current results demonstrate that PFC dopaminergic neurotransmission 
contributes to the regulation of attentional lapses during sleep deprivation without changing 
neurophysiological markers of sleep homeostasis. Intriguingly, selective inhibition of COMT can even 
reverse the expected beneficial effects of pharmacologically enhanced dopaminergic tone after 
sleep deprivation. This finding has important implications, given the increased use of stimulants in 
healthy people aiming at improved vigilance and cognitive functions (Farah, 2015; Smith and Farah, 
2011). Nevertheless, the data presented here were obtained in healthy young men and the results of 
this study may not be generalized to women and older individuals. Future pharmacogenetics studies 
are warranted to disentangle the complex roles of the dopaminergic system in regulating human 
sleep-wake behavior and physiology. 
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Table 1. Demographic characteristics of participants in ‘Sleep Deprivation’ (SD) study. 
 Val/Val Val/Met Met/Met F2,70 p 
Sample size 17 35 21   
Age (years) 24.6 ± 4.0 23.8 ± 3.1 23.5 ± 2.3 0.68 0.58 
Body mass index (kg/m2) 22.5 ± 2.2 22.3 ± 1.6 22.6 ± 2.2 0.18 0.83 
Alcohol consumption (drinks/week) 2.4 ± 2.6 3.6 ± 2.8 3.3 ± 3.5 0.87 0.42 
Caffeine consumption (mg/day) 147 ± 186 121 ± 119 148  ± 109 0.35 0.7 
Epworth Sleepiness Scale 7.9 ± 2.6 6.5 ± 2.5 6.3 ± 2.5 1.7 0.19 
Munich ChronoType Questionnaire 4.3 ± 1.0 4.3 ± 0.9 4.2 ± 0.9 0.18 0.83 
Trait Anxiety 36.1 ± 9.6 33.9 ± 7.8 34.3 ± 6.8 0.46 0.63 
 
F- and p-values from ANOVA with factor ‘genotype’. Estimates of caffeine consumption were based 
on the following average caffeine content per serving: coffee, 100 mg; energy drink (2 dl), 80 mg; 
cola drink (2 dl), 40 mg; black or green tea, 30 mg; chocolate (100 g), 50 mg [same as: (Valomon et 
al, 2014)]. Higher Epworth Sleepiness Scale scores (Johns, 1991) indicate higher daytime sleepiness. 
Munich ChronoType Questionnaire score (Wirz-Justice et al, 2003) indicates the mid-sleep time on 
leisure days, including an estimated correction for the sleep debt accumulated during the work 
week, age and sex. Trait Anxiety Inventory (Spielberger et al, 1970). Means ± SD. 
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Table 2. Demographic characteristics of participants in ‘Sleep Deprivation and Tolcapone’ (SD&T) 
study. 
 Val/Val Val/Met Met/Met F2,27 p 
Sample size 10 10 10   
Age (years) 23.7 ± 2.4 23.3 ± 1.6 23.3 ± 2.0 0.11 0.89 
Body mass index (kg/m2) 21.9 ± 1.4 22.4 ± 1.4 22.9 ± 1.4 1.16 0.33 
Alcohol consumption (drinks/week) 1.8  ±  1.6 2.9  ±  2.8 2.7  ±  2.0 0.71 0.50 
Caffeine consumption (mg/day) 110 ± 112 66 ± 47 134  ± 106 1.38 0.23 
Epwort Sleepiness Scale 6.1 ± 3.5 5.8 ± 3.2 7.1 ± 3.3 0.42 0.66 
Pittsburgh Sleep Quality Index 3.6 ± 2.01 3.4 ± 1.7 4.7 ±  1.6 1.57 0.23 
Munich ChronoType Questionnaire 4.0 ± 0.9 4.2 ± 1.2 4.4 ± 1.2 0.38 0.69 
Trait Anxiety 32.9 ± 9.2 32.8 ± 7.6 33.1 ± 8.6 0 1 
Beck Depression Inventory (BDI-II) 5.7 ± 4.7 4.1 ± 3.7 3.9 ± 4.7 0.5 0.61 
Extraversion (EPQ) 6.5 ± 3.6 8.6 ± 2.7 7.8 ± 3.4 1.07 0.36 
Neuroticism (EPQ) 2.8 ± 2.6 1.9 ± 1.9 3.2 ± 2.4 0.82 0.45 
Psychoticism (EPQ) 3.5 ± 2.3 4.3 ± 2.6 3.0 ± 2.3 0.76 0.48 
 
F- and p-values from ANOVA with factor ‘genotype’. Estimates of caffeine consumption were based 
on the following average caffeine content per serving: coffee, 100 mg; energy drink (2 dl), 80 mg; 
cola drink (2 dl), 40 mg; black or green tea, 30 mg;  chocolate (100 g), 50 mg [same as: (Valomon et 
al, 2014)]. Higher Pittsburgh Sleep Quality Index scores (Buysse et al, 1989) indicate lower sleep 
quality. Higher Epworth Sleepiness Scale scores (Johns, 1991) indicate higher daytime sleepiness. 
Munich ChronoType Questionnaire score (Wirz-Justice et al, 2003) indicates the mid-sleep time on 
leisure days, including an estimated correction for the sleep debt accumulated during the work 
week, age and sex. Trait Anxiety Inventory (Spielberger et al, 1970). EPQ, Eysenck Personality 
Questionnaire, revised short German version (Ruch, 1999). Beck Depression Inventory (BDI-II). 
Means ± SD. 
1 For the PSQI, one study participant missing.  
 
Figure Legends 
Figure 1. Lapses of attention (i.e., trials on a 10-min PVT with reaction times > 500 ms, expressed as 
a percentage of all trials in a quintile) across 40 hours of sustained wakefulness, split by COMT 
genotypes. (A) PVT lapses (y-axis) as a function of time on task (z-axis) and time awake (x-axis). The 
warmer the colors, the higher the lapse frequency. The 3D plots are split by COMT genotypes (left 
panel: Val/Val; middle panel: Val/Met; right panel: Met/Met). (B) Comparison of lapse frequencies in 
baseline (day 1) and after sleep deprivation (day 2), split by COMT genotypes (Val/Val: red line; 
Val/Met: black line; Met/Met: blue line). Values represent estimated means ± standard error; p-
value (p < 0.0006) withstands Bonferroni correction (p < 0.016). 
Figure 2. The homeostatic build-up in sleep pressure is indistinguishable among COMT genotypes 
and not affected by tolcapone. (A) Evolution of 1-9 Hz activity in the waking EEG across 40 hours 
prolonged wakefulness. EEG activity in placebo (open circles) and tolcapone (filled circles) conditions 
was expressed as a percentage of the mean values at 08:00, 11:00, 14:00, and 17:00 on the baseline 
day (dashed horizontal line), split by COMT genotypes (Val/Val: red line; Val/Met: black line; 
Met/Met: blue line). Administration of tolcapone at 7:00 pm and 7:00 am is indicated with capsule 
and vertical dashed lines. Three-way mixed-model ANOVA with the factors ‘genotype’, ‘treatment’ 
and ‘time’ yielded significant effects of ‘time’, yet no significant effects and interactions with 
‘genotype’ or ‘treatment’ (see main text). (B) Dynamics of mean SWA across NREM sleep episodes 1-
4 in baseline (mean of two baseline nights) and recovery nights. EEG activity (means ± SEM) in 
placebo (open circles) and tolcapone conditions (filled circles) was expressed as a percentage of the 
mean all-night values in baseline (dashed horizontal line), split by COMT genotypes (Val/Val: red line; 
Val/Met: black line; Met/Met: blue line). Three-way mixed-model ANOVA with the factors 
‘genotype’, ‘condition’ and ‘NREM sleep episodes’ yielded significant effects of ‘episode’, ‘condition’ 
and ‘cycle’ x ‘condition’, yet no significant interactions involving ‘genotype’ (see main text). Values 
represent estimated means ± standard error. 
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* p < 0.05 (tolcapone recovery vs. mean baseline; paired, 2-tailed t-tests) 
+ p < 0.05 (placebo recovery vs. mean baseline; paired, 2-tailed t-tests). 
Figure 3. The increase in attentional lapses on a 10-min PVT after sleep deprivation is exacerbated 
by the COMT inhibitor tolcapone and modulated by COMT genotype. (A) Average lapse frequencies 
after sleep deprivation (day 2) in placebo (white) and tolcapone (black) conditions. Bars represent 
means ± SEM (n = 30). (B) Evolution of lapse frequency on the PVT, split by treatment (placebo: open 
circles; tolcapone: filled circles) and genotype (Val/Val: red; Val/Met: black; Met/Met: blue). 
Estimated means ± standard error (n = 10 per group). Tolcapone administration is indicated with 
vertical lines. 
* p < 0.0004 (tolcapone vs. placebo; withstanding Bonferroni correction) 
Figure 4. Schematic illustration of the proposed relationships between PFC dopamine transmission 
and attentional lapses in baseline (green shading), after sleep deprivation (orange shading), and 
after sleep deprivation and tolcapone administration (yellow shading), split by COMT genotypes 
(Val/Val: red; Val/Met: black; Met/Met: blue). The data suggest an inverse U-shape relationship 
between PFC dopamine transmission and lapse frequency. While the increase in PFC dopamine 
transmission with sleep deprivation may be relatively more pronounced in Val/Val than in Val/Met 
and Met/Met allele carriers, tolcapone reduces COMT activity to roughly the same level in all three 
genotypes (Apud et al, 2007). Asterisks indicate impacts of genotype and tolcapone treatment after 
sleep deprivation. SD = ‘sleep deprivation study’; SD&T = ‘sleep deprivation and tolcapone study’. 
See Discussion for details. 
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Supplementary Table S1: Tolcapone has no effect on polysomnographic and subjective markers of sleep quality in baseline and recovery nights. 
 Placebo condition Tolcapone condition Factor ‘condition’ 
 
Baseline Recovery Baseline Recovery F1,79 p 
Stage 1 (min) 30.1 ± 10.9 14.6 ± 8.0 30.3 ± 16.2 15.4 ± 8.4 131.2 < 0.0001 
Stage 2 (min) 219.7 ± 29.2 207.7 ± 31.6 221.5 ± 29.2 202.6 ± 32.3 17.0 < 0.0001 
Slow wave sleep (min) 89.8 ± 23.0 141.5 ± 35.9 89.4 ± 25.1 138.6 ± 23.6 367.5 < 0.0001 
NREM sleep (min) 309.5 ± 23.7 349.2 ± 28.1 310.9 ± 24.4 341.1 ± 26.2 122.1 < 0.0001 
REM sleep (min) 110.8 ± 22.9 104.7 ± 24.7 110.3 ± 21.2 112.5 ± 23.9 1.5 0.22 
WASO (min) 7.4 ± 10.1 1.6 ± 2.3 8.3 ± 13.1 1.3 ± 2.2 27.2 < 0.0001 
Total sleep time (min) 450.4 ± 16.5 468.6 ± 6.2 451.5 ± 20.2 469.0 ± 5.4 41.4 < 0.0001 
Sleep episode (min) 462.7 ± 14.9 475.7 ± 5.4 463.7 ± 15.9 475.7 ± 3.6 20.6 < 0.0001 
Sleep efficiency (%) 93.9 ±  3.4 97.6 ± 1.3 94.1 ± 4.2 97.7 ± 1.1 61.2 < 0.0001 
Sleep latency (min) 15.3 ± 10.4 4.3 ± 5.4 16.2 ± 16.0 4.3 ± 3.6 42.4 < 0.0001 
REM sleep latency (min) 75.7 ± 24.7 72.1 ± 29.2 68.4 ± 18.7 71.2 ± 25.7 0.0 0.85 
EEG SWA (μV2) 131.1 ± 8.1 164.9 ± 10.9 128.0 ± 8.2 168.7 ± 11.1 189.4 < 0.0001 
Subjective sleep quality       
Sleep latency (min) 16.1 ± 9.2 6.4 ± 4.7 17.0 ± 9.3 8.5 ± 9.0 43.5 < 0.0001 
Number of awakenings  2.2 ± 2.2 0.8 ± 0.7 2.1 ± 1.4 1.2 ± 1.0 22.3 < 0.0001 
Time spent awake (min) 19.9 ± 26.1 7.1 ± 11.8 16.1 ± 25.4 4.8 ± 6.2 14.8 0.0002 
Sleep intensity (VAS) 50.0 ± 16.3 73.5 ± 12.9 47.8 ± 17.8 66.0 ± 17.8 67.9 < 0.0001 
Mood state (VAS) 53.1 ± 14.6 55.1 ± 13.1 50.3 ± 11.4 51.7 ± 14.8 1.2 0.27 
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Values represent means ± SD. Visually scored sleep variables (‘polysomnography’) are derived from the first 480 minutes from lights-off, in 10 individuals of 
each genotype groups  (except for n = 9 in Val/Val genotype in recovery nights due to artefacts in recordings). Stages 1 and s2 = NREM sleep stages 1 and 2; 
Slow wave sleep = combined NREM sleep stages 3 and 4; WASO = wakefulness after sleep onset; TST = total sleep time; Sleep episode = time after sleep 
onset until final awakening; Sleep efficiency = percentage of TST per 480 min; Sleep latency = time from lights-off to first occurrence of stage 2; REM sleep 
latency = time from sleep onset to first occurrence of REM sleep; EEG SWA = slow-wave activity, spectral power in 0.5-4.5 Hz range. Subjective sleep quality 
was assessed with 100-mm visual analogue scales (VAS) administered upon awakening. Subjectively perceived sleep intensity was estimated from two 
questions about how calm and deep sleep was, and subjective mood state represents an average score of five ratings about feeling recovered, happy, 
energetic, calm, and focused. 
F- and p-values: mixed-model ANOVA with the factors ‘condition’, ‘COMT genotype’, and ‘treatment’. No significant main effects and interactions with 
factors ‘COMT genotype’ and ‘treatment’ were found. 
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Supplementary Figure S1. Flow chart for enrollment of study participants and randomization into 
drug order groups. 
 
a Reasons for exclusion after screening: < 80 % sleep efficiency in screening night, n = 6; positive drug 
screen, n = 1. 
b Reasons for no enrollment despite successful screening: scheduled study dates were not possible 
due to work obligations or illness, loss of contact with potential study participants, objective of 10 
participants per genotype was reached. 
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Supplementary Figure S2. Evolution of median PVT response speed and subjective state during prolonged waking. 
 
Data represent means ± SEM in 30 study participants, split by treatment (placebo: white symbols; tolcapone: black symbols). Mixed-model ANOVA 
indicated highly significant effects of ‘time’ (pall < 0.0001), yet no significant main effects or interactions of the factors ‘COMT genotype’ and ‘treatment’. 
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The following task and questionnaires were employed: (a) median speed on the psychomotor vigilance task (PVT); (b) (a) Karolinska Sleepiness Scale (KSS; 
range 0-9); (c) Tiredness Symptom Scale (TSS; range 0-14); (d-f) Visual Analogue Scales (VAS; ranges 0-100); (g-i) Profile of Mood States (POMS; ranges 0-
42). 
 
